{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:47:40Z","timestamp":1787593660650,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1ZIADK032103"],"award-info":[{"award-number":["1ZIADK032103"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["1ZIAAI005095"],"award-info":[{"award-number":["1ZIAAI005095"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006084","name":"National Institutes of Health Office of AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006084","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.03.039","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:46:06Z","timestamp":1743137166000},"page":"3147-3162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["An engineered antibody-lectin conjugate targeting the HIV glycan shield protects humanized mice against HIV challenge"],"prefix":"10.1016","volume":"33","author":[{"given":"Rashmi","family":"Kumariya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lusvarghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijy","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Doria-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-0852","authenticated-orcid":false,"given":"Carole A.","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.039_bib1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev-biophys-060414-034156","article-title":"Structure and Immune Recognition of the HIV Glycan Shield","volume":"47","author":"Crispin","year":"2018","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.ymthe.2025.03.039_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nm0403-393","article-title":"HIV-1: nature's master of disguise","volume":"9","author":"Mascola","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(05)70271-1","article-title":"Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV","volume":"5","author":"Balzarini","year":"2005","journal-title":"Lanc. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.039_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10719-021-10015-x","article-title":"35 years in plant lectin research: a journey from basic science to applications in agriculture and medicine","volume":"39","author":"Van Damme","year":"2022","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ymthe.2025.03.039_bib5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/molecules20010648","article-title":"Lectins with anti-HIV activity: a review","volume":"20","author":"Akkouh","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2025.03.039_bib6","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae","volume":"84","author":"O'Keefe","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib7","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"Mori","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.039_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mam.2016.04.004","article-title":"Emerging roles of protein mannosylation in inflammation and infection","volume":"51","author":"Loke","year":"2016","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/v8100296","article-title":"Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 8","volume":"8","author":"Lusvarghi","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.039_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acsinfecdis.6b00139","article-title":"Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles","volume":"2","author":"Lusvarghi","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.03.039_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/v8120331","article-title":"Pharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential Uses","volume":"8","author":"Barton","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.039_bib12","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2019.07.021","article-title":"Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope","volume":"27","author":"Hamorsky","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.039_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0300985820948822","article-title":"Human CD34(+) Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features","volume":"58","author":"Blumich","year":"2021","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12977-020-00516-2","article-title":"Benefits and limitations of humanized mice in HIV persistence studies","volume":"17","author":"Marsden","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymthe.2025.03.039_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0684.2007.00242.x","article-title":"Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide","volume":"36","author":"Emau","year":"2007","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1089\/aid.2012.0026","article-title":"Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains","volume":"28","author":"Ferir","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.ymthe.2025.03.039_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.str.2006.05.017","article-title":"Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding","volume":"14","author":"Ziolkowska","year":"2006","journal-title":"Structure"},{"key":"10.1016\/j.ymthe.2025.03.039_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.str.2010.05.016","article-title":"Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity","volume":"18","author":"Moulaei","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.ymthe.2025.03.039_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.039_bib20","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.039_bib21","first-page":"1098","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2025.03.039_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12575-017-0060-7","article-title":"Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells","volume":"19","author":"Fang","year":"2017","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.ymthe.2025.03.039_bib24","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/cb300130k","article-title":"Revisiting the role of glycosylation in the structure of human IgG Fc","volume":"7","author":"Borrok","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JIR.S121233","article-title":"Fc gamma receptors: glycobiology and therapeutic prospects","volume":"9","author":"Hayes","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ymthe.2025.03.039_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.039_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.2910190505","article-title":"Characterization of EBV-genome negative \"null\" and \"T\" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma","volume":"19","author":"Schneider","year":"1977","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.039_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies","volume":"11","author":"Haynes","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2018338118","article-title":"Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site","volume":"118","author":"Conti","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-019-1101-y","article-title":"Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET","volume":"568","author":"Lu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.039_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1517\/14728222.2015.1010513","article-title":"HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth","volume":"19","author":"Acharya","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymthe.2025.03.039_bib33","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1002\/anie.201500157","article-title":"Glycopeptide mimetics recapitulate high-mannose-type oligosaccharide binding and function","volume":"54","author":"Lusvarghi","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ymthe.2025.03.039_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01084-19","article-title":"Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126","volume":"64","author":"Fischer","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2025.03.039_bib35","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1038\/s41467-018-06349-0","article-title":"Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo","volume":"9","author":"Derby","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.039_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ma16165547","article-title":"Sustained Delivery of the Antiviral Protein Griffithsin and Its Adhesion to a Biological Surface by a Silk Fibroin Scaffold","volume":"16","author":"Guan","year":"2023","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.039_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54493-4","article-title":"Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa","volume":"9","author":"Gunaydin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.03.039_bib38","first-page":"a22","article-title":"A Phase 1a\/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis","volume":"6","author":"Nabeta","year":"2022","journal-title":"Univ. Louisville J. Respir. Infect."},{"key":"10.1016\/j.ymthe.2025.03.039_bib39","article-title":"Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ymthe.2025.03.039_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12977-018-0455-9","article-title":"Antibody-mediated prevention and treatment of HIV-1 infection","volume":"15","author":"Gruell","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymthe.2025.03.039_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","article-title":"Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody","volume":"180","author":"Schommers","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.03.039_bib43","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2010-02-270678","article-title":"Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence","volume":"116","author":"Strowig","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.039_bib44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1128\/JVI.02566-13","article-title":"Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2018.07.004","article-title":"CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS","volume":"157","author":"Tian","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2025.03.039_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008082","article-title":"IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies","volume":"15","author":"Bi","year":"2019","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2025.03.039_bib47","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib48","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221247120","article-title":"Complement contributes to antibody-mediated protection against repeated SHIV challenge","volume":"120","author":"Goldberg","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","article-title":"The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans","volume":"20","author":"Smith","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.039_bib51","article-title":"Trogocytosis targeting chimeras (TrogoTACs) for targeted protein transfer","author":"Till","year":"2024","journal-title":"ChemRxiv"},{"key":"10.1016\/j.ymthe.2025.03.039_bib52","doi-asserted-by":"crossref","first-page":"IA009","DOI":"10.1158\/1535-7163.TARG-23-IA009","article-title":"Antibody-lectin chimeras for glyco-immune checkpoint blockade","volume":"22","author":"Stark","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2025.03.039_bib53","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.039_bib54","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","article-title":"An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.039_bib55","first-page":"12.11.1","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays","volume":"Chapter 12","author":"Montefiori","year":"2005","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215163","article-title":"Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting","volume":"14","author":"Cheng","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.039_bib57","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.212511599","article-title":"Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus\/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic","volume":"99","author":"Imamichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib58","doi-asserted-by":"crossref","first-page":"19769","DOI":"10.1073\/pnas.1217443109","article-title":"Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains","volume":"109","author":"Shingai","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/jvi.62.1.139-147.1988","article-title":"In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity","volume":"62","author":"Willey","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib61","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.039_bib62","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1128\/jvi.76.5.2123-2130.2002","article-title":"Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies","volume":"76","author":"Nishimura","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2025.03.039_bib63","doi-asserted-by":"crossref","first-page":"9130","DOI":"10.1038\/s41598-017-07966-3","article-title":"One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:11:02Z","timestamp":1765804262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625002138"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.039","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An engineered antibody-lectin conjugate targeting the HIV glycan shield protects humanized mice against HIV challenge","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}